This led to a dose-dependent restoration of downstream effector genes KLF4 and INPP5F, significantly improving cardiac hypertrophy parameters and alleviating myocardial hypertrophy (Yuan et al., 2017). The gene discussed is KLF4; the disease is cardiac hypertrophy.